Skip to main content
. 2022 Mar 31;2022:6160563. doi: 10.1155/2022/6160563

Table 2.

Vasopressor use and peripheral catheter data (n = 369).

Variables
Vasopressor medication used Dopamine 32 (8.7%)
Epinephrine 279 (75.6%)
Norepinephrine 42 (11.4%)
Milrinone 93 (25.2%)
Maximum dose of vasopressor medication used (µg/kg/min) Dopamine 15
Epinephrine 0.25
Norepinephrine 0.2
Milrinone 0.8
Median duration of vasopressor medication used (hours) (IQR) 24 (13–48)
Vasopressor inotropic score <5 147 (39.8%)
5–10 167 (45.3%)
11–15 29 (7.9%)
16–20 20 (5.4%)
>20 6 (1.6%)
Vasopressor inotropic score (median; IQR) 8 [5–10]
Coadministration of vasopressor medication 77 (20.9%)
Size of peripheral IV catheter 18 20 (5.4%)
20 69 (18.7%)
22 101 (27.4%)
24 179 (48.5%)
Conversion to central venous catheter (CVC) 127 (34.4%)
Reason for CVC conversion Persistent high inotropic support 30 (8.1%)
Difficulty to maintain PIV 14 (3.8%)
Persistent acidosis 32 (8.7%)
Need for multiple infusions 6 (1.6%)
Monitoring 13 (3.5%)
Unknown 30 (8.1%)
Time to CVC; hours (median; IQR) 7 [5–12]
Extravasation 8 (2.2%)

IQR=interquartile range.